Results 71 to 80 of about 6,025 (196)

Prospective Evaluation of Serial Biomarkers in Patients With Intermediate High Risk Acute Pulmonary Embolism: A Single Center Proof‐of‐Concept Study

Pulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Patients diagnosed with intermediate high‐risk pulmonary embolism (IHRPE) are at significant risk for clinical deterioration during hospitalization; however, clinical tools to identify which patients will worsen are imprecise. We designed a proof‐of‐concept, single‐center prospective study to assess IHRPE patients (using 2019 ESC criteria ...
Hilamber Subba, Ariel McKenna, John Gilboy, Jacob Gelman, Jessica Evans, Alex Smith, James Kerney, Joel A. Wirth   +7 more
wiley   +1 more source

Efficacy and Safety of Low‐Dose Prolonged Infusion Thrombolysis With rt‐PA for Acute Intermediate‐High Risk Pulmonary Embolism

Pulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Thrombolytic therapy alleviates pulmonary embolism (PE) symptoms rapidly but increases bleeding risk, with no consistent consensus on acute intermediate‐high risk PE. This study evaluated the efficacy and safety of low‐dose prolonged infusion thrombolysis for acute intermediate‐high risk PE to provide a safer clinical option.
Wenxiang Qi, Maofeng Gong, Hao Huang, Yangyi Zhou, Haobo Su   +4 more
wiley   +1 more source

Comparison of the safety and efficacy of dual antiplatelet therapy versus tenecteplase in patients with minor nondisabling acute ischemic stroke

Scientific Reports
To evaluate the safety and efficacy of dual antiplatelet therapy (DAPT) versus tenecteplase in minor non-disabling acute ischemic stroke. This retrospective observational study utilized data from our stroke database.
Xinzhao Jiang, Ruozhen Yuan, Jiawei Ye, Xu Wang, Zongjie Shi, Shunyuan Guo   +5 more
doaj   +1 more source

Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial

Stroke and Vascular Neurology
Background The benefit of intravenous alteplase in acute ischaemic stroke (AIS) is time-dependent. Tenecteplase is non-inferior to alteplase among patients with AIS.
Bruce C V Campbell, Yongjun Wang, Yilong Wang, Zixiao Li, Xingquan Zhao, David Wang, Yunyun Xiong, Hao Li, Xia Meng, Yuesong Pan, Lee H Schwamm, Aoming Jin, Mark W Parsons, Huaguang Zheng, Shuya Li, Runhui Li, Marc Fisher, Runqi Wangqin, Ziran Wang, Deyang Li, Hongguo Dai, Junhai Wang   +21 more
doaj   +1 more source

Tenecteplase: biochemical and clot lysis activity comparisons

Frontiers in Pharmacology
IntroductionIn the last decades, the recombinant tissue plasminogen activator alteplase has been the standard fibrinolytic treatment of acute myocardial infarction, pulmonary embolism, and acute ischemic stroke.
Jan Bechmann, Ira Schmid, Simone Brand, Felix Miller, Chengzhi Zhang   +4 more
doaj   +1 more source

Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator [PDF]

, 2013
PURPOSE. To investigate whether tissue plasminogen activator (tPA) can prevent and/or reverse steroid-induced IOP elevation in an ovine model. METHODS.
Alvarez, Larry, Candia, Oscar, Danias, John, Gerometta, Rosana María del Rosario, Kumar, Sandeep, Shah, Shaily   +5 more
core   +2 more sources

Implementation of a Tenecteplase Protocol for Treatment of Acute Ischemic Stroke in a Health System

INNOVATIONS in Pharmacy
Purpose. Alteplase is the standard of care for intravenous thrombolytic treatment of acute ischemic stroke, but recent evidence suggests that tenecteplase may be as safe and efficacious. The purpose of this study was to evaluate the direct cost savings,
Alexis Pace, Maya Wai, Ethan Frye
doaj  

A Systematic Review of the Efficacy and Safety of Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Time to Pass the Torch

Stroke: Vascular and Interventional Neurology
Alteplase, a biosynthetic form of human tissue‐type plasminogen activator, is Food and Drug Administration‐approved for the treatment of acute ischemic stroke and currently the standard of care for thrombolytic therapy.
Miguel Rodriguez, Christian Sidebottom, Drew A. Wells, Thirumalaivasan Dhasakeerthi, Lisa Hayes, Cheran Elangovan, Balaji Krishnaiah   +6 more
doaj   +1 more source

Alteplase- and Tenecteplase-Related Errors and Risk Mitigation Strategies in the Treatment of Acute Ischemic Stroke: A Study of Event Reports From 52 Hospitals

Patient Safety
# Background Alteplase and tenecteplase are thrombolytic agents used to treat patients with acute ischemic stroke (AIS). Despite the convenient bolus dosing of tenecteplase, its off-label use for AIS creates new patient safety challenges that are ...
Myungsun Ro, Matthew A. Taylor, Rebecca Jones   +2 more
doaj   +1 more source

Outpatient treatment of low-risk venous thromboembolism with monotherapy oral anticoagulation: patient quality of life outcomes and clinician acceptance [PDF]

, 2016
BACKGROUND: Oral monotherapy anticoagulation has facilitated home treatment of venous thromboembolism (VTE) in outpatients. OBJECTIVES: The aim of this study was to measure efficacy, safety, as well as patient and physician perceptions produced by
Beam, Daren M., Kahler, Zachary P., Kline, Jeffrey A.   +2 more
core   +2 more sources